Rinvoq (Upadacitinib) Clinical Guidelines and Efficacy

Approved Indications and Dosing

The American Gastroenterological Association considers Rinvoq a "HIGHER efficacy medication" for ulcerative colitis 1
Higher doses (30 mg daily) of Rinvoq demonstrate the highest efficacy at reducing EASI scores and were superior to dupilumab in head-to-head clinical trials 2
Rinvoq demonstrated superior efficacy compared to adalimumab in combination with methotrexate in head-to-head studies for rheumatoid arthritis 3
The standard dosing for Rinvoq in atopic dermatitis is 15 mg or 30 mg once daily 2
The standard dosing for Rinvoq in ulcerative colitis is 45 mg once daily for induction (8-16 weeks), followed by 15 mg or 30 mg once daily for maintenance 1, 4
The standard dosing for Rinvoq in rheumatoid arthritis is 15 mg once daily 3
The dosing for Rinvoq in Crohn's disease varies, but typically 45 mg for induction followed by 15 or 30 mg for maintenance 5, 6

For patients with severe renal impairment (creatinine clearance < 30 mL/min), the maximum recommended dosage of Rinvoq is 15 mg daily 7, 8
For patients with severe hepatic disease (Child-Pugh C), Rinvoq is not recommended 7, 8
Dose reduction to 15 mg daily may be appropriate for patients aged ≥75 years 3
Complete blood count with differential, liver enzymes should be checked at baseline, and after initiation or dose-escalation of Rinvoq 2
Lipids should be checked after initiation (4 weeks for abrocitinib, 12 weeks for upadacitinib) of Rinvoq 2
Testing for viral hepatitis, tuberculosis, and pregnancy should be performed at baseline 2

History of venous thromboembolism (VTE) is a risk factor requiring special consideration for Rinvoq 7, 8
Age > 65 years is a risk factor requiring special consideration for Rinvoq 7, 8
Current or previous long-term smokers are at increased risk when taking Rinvoq 4
History of cardiovascular disease is a risk factor requiring special consideration for Rinvoq 4
History of cancer is a risk factor requiring special consideration for Rinvoq 4
Pregnancy is a risk factor requiring special consideration for Rinvoq, as limited data is available and animal studies suggest potential adverse effects 4, 8

The FDA recommends the use of JAK inhibitors, such as Rinvoq, in patients with prior failure or intolerance to TNF antagonists 1, 4
The European Medicines Agency recommends cautious use of JAK inhibitors, such as Rinvoq, as first-line agents in patients at risk for adverse cardiovascular outcomes 1, 4

The American Gastroenterological Association recommends that upadacitinib can be used in patients with pre-existing cardiac disease, but requires careful risk stratification, enhanced monitoring, and should generally be avoided in patients ≥65 years with multiple cardiovascular risk factors unless no suitable alternatives exist 9
Patients with age ≥65 years and any cardiovascular risk factor should avoid upadacitinib unless no alternatives exist, according to the American College of Cardiology 9
Current or previous long-term smokers with cardiac history should be carefully evaluated before initiating upadacitinib, as recommended by the American Heart Association 9
The FDA recommends JAK inhibitors like upadacitinib only after failure or intolerance to TNF antagonists, while the European Medicines Agency advises cautious first-line use in patients at risk for adverse cardiovascular outcomes, with a strength of evidence based on recent large-scale analyses 9

Stable coronary artery disease is not an absolute contraindication for upadacitinib, but requires enhanced cardiovascular monitoring, as suggested by the American College of Cardiology 9
Do not use upadacitinib as first-line therapy in patients ≥65 years with cardiovascular risk factors when TNF inhibitors remain viable options, according to the American Gastroenterological Association 9
Do not ignore smoking status—current or past smokers with cardiac disease represent the highest-risk population, as emphasized by the American Heart Association 9